Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released pivotal new data from its Phase 2b HERIZON-BTC-01 clinical trial assessing zanidatamab in previously treated HER2-positive biliary tract cancer (BTC). The study’s findings were prominently featured at the American Society of Clinical Oncology (ASCO) Annual Meeting today, highlighting significant improvements in overall survival rates and continued positive responses […]
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) have entered into a definitive agreement, marking a significant milestone in the development of new cancer treatments. Under this agreement, Jazz will acquire Redx’s promising KRAS (Kirsten rat sarcoma virus) inhibitor program, highlighting a strategic move to enhance Jazz’s early-stage oncology pipeline with innovative […]
Axsome Therapeutics has agreed to acquire Sunosi (solriamfetol), an approved dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI), from Jazz Pharmaceuticals. Sunosi is indicated to improve wakefulness in adults having excessive daytime sleepiness (EDS) because of narcolepsy or obstructive sleep apnea (OSA). The DNRI was approved in 2019 by the US Food and Drug Administration (FDA) […]
Rylaze FDA approval : Jazz Pharmaceuticals has secured approval for its leukemia drug Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn or JZP458) from the US Food and Drug Administration (FDA). The Irish biopharma company bagged the approval for the drug to be used as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic […]
In a significant move within the pharmaceutical industry, Irish biopharma company Jazz Pharmaceuticals has announced an agreement to acquire British-based GW Pharmaceuticals in a monumental $7.2 billion cash-and-stock transaction. This acquisition is set to create a powerhouse in the neuroscience field with a robust global commercial and operational footprint. Strategic Acquisition to Enhance Neuroscience Portfolio […]
